CA2146547A1 - Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection - Google Patents
Method and composition for treating muco-epidermal and epidermal pain, inflammation and infectionInfo
- Publication number
- CA2146547A1 CA2146547A1 CA002146547A CA2146547A CA2146547A1 CA 2146547 A1 CA2146547 A1 CA 2146547A1 CA 002146547 A CA002146547 A CA 002146547A CA 2146547 A CA2146547 A CA 2146547A CA 2146547 A1 CA2146547 A1 CA 2146547A1
- Authority
- CA
- Canada
- Prior art keywords
- epidermal
- preparation
- steroidal anti
- inflammatory agent
- chlorhexidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A topical pharmaceutical preparation for the treatment of epidermal and muco-epidermal tissue is provided. The composition includes a therapeutic amount of chlorexidine and at least one non-steroidal anti-inflammatory agent. A method for treating epidermal and muco-epidermal, pain, inflammation, infection and lesion by applying the topical preparation directly to the affected site is also provided.
Description
WO 95/04s20 2 14 ~ ~ 7 PCT/uss4lo8944 ~THOD ~ND COMPOSmON FOR TREATING MUCO-FPIDFRMAL AND
nFRl~AL PAIN, INFLAMMATION AND INFECTION
BACKGROUND OF I~F. INVENIION
The present invention relates generally to pharmaceutical preparations for the treatment of muco-epidermal and epidermal tissue.
More particularly, the present invention relates to gels, creams, solutions and other topical preparations including a mixture of chlorhexidine and at least one non-steroidal anti-iIlflAmmAtory agent. The invention further provides a method for the treatment of muco-epidermal and epitlermAl tissue using such preparations.
The antimicrobial effects of chlorhexidine are well-documented.
Chlorhexidine gels, rinses and creams are routinely used to control bacterial infections on mucosal epi-l~rmAl and epic~rmAl tissue. For example, chlorhexidine gels and rinses are widely used in dentistry for the treatment of periodontal disease. Non-steroidal anti-ir fl~mmAtory agents such as ibuprofen, ketoprofen and indomethacin have applicAtion in the treatment of, for example, inflAmmAtory diseases such as arthritis, general muscle, skeletal and joint pain and menstrual cramps.
While these compounds have been widely used individually by physicians and dentists in the above-described manner for many years, the effectiveness of a combination of chlorhexidine and a non-steroidal anti-i~flAmmAtory agent has not been appreciated.
Accordingly, it is the object of the present invention to provide a pharmaceutical preparation including a combination of chlorhexidine and at least one anti-i~flAmmAtory agent which together show a synergistic effect in the treatment of muco-epi~lermAl and epidermal irlflAmmAtion and infection.
It is a further object of the invention to provide a method for treating muco-epidermal and epidermal tissue using such preparations.
SUMMARY OF THE INVENTION
The present invention meets the above-stated objects and others that will become readily apparent by providing topical pharmaceutical preparations which include chlorhexidine and at least one non-steroidal anti-irflAmmAtory agent. These active ingredients are incorporated into a gel, cream, solution, rinse or other pharmaceutically acceptable carrier and are applied topically to sites of epi~1ermAl and muco-epidermal inflammation, infection or lesion.
wo 95/04520 æ~465 4~ PCT/US94/08944 The preparations which are the subject of the present invention include a non-toxic amount of chlorhexidine and preferably include, as the non-steroidal anti-inflammatory agent, indomethacin, ibuprofen, ketoprofen or other prostaglandin inhibitors.
As demonstrated below by the various examples provided, the combination of chlorhexidine and a non-steroidal anti-inflAmm~tory agent unexpectedly show a synergistic effect in the treatment of a number of conditions including, periodontal disease, acne, post-r~iAtion therapy, post-chemotherapy therapy, post-surgical therapy, burns and non-specific epidermal and muco-epidermal infections.
The present invention is also directed to a method for treating epi~rm~l and muco-epidermal tissue employing the above-described topical preparations. The course of therapy with such preparations generally requires one to three applications per day or is applied on an as needed basis, depending on the severity of the ronr~ition. Treatment includes directly applying the topical preparations to the affected site.
DRT~ D DF~ lONOF TH~ TION
As noted above, the-topical pharmaceutical preparations of the present invention include chlorhexidine in a therapeutically effective amount. For most therapies, from about 0.1 wt.% to about 1.0 wt.%, preferably about 0.2 wt.% of chlorhexidine, has been found to be effective. The preparations further include a non-toxic amount of at least one non-steroidal anti-inflammatory agent, most preferably indocin, ibuprofen and/or ketoprofen, in an amount ranging from about 2 wt.% to about 5 wt.% of the total preparation.
The active ingredients are incorporated into a solution, cream, rinse, lotion, gel or other acceptable carrier. In some instances, depending upon the particular carrier, the active ingredients are first solubilized and then incorporated into the carrier. The addition of a suspending agent to the carrier such as, for example, acacia powder, xanthan gum, methylcellulose, hydroxymethylcellulose or hydroxypropylcellulose, has been found to be particularly useful when compounding the carrier. In this regard, hydroxymethylcellulose gel is the ~reL~led carrier where treatment requires manual application of the preparation to affected epidermal or muco-epidermal tissue.
Fxample I
Ten patients exhibiting advanced periodontal disease were treated with a preparation of 0.2% chlorhexidine and 2% ketoprofen incorporated into a 2 ~ PCT/US94/08944 hydroxymethylcellulose gel. The patients were each instructed to apply one of the preparations to the affected gums with a tooth brush twice a day for a week. All of these patients experienced relief from pain, infection and inflammation after the prescribed course of therapy.
Fxample II
Two surgical patients were instructed to apply the preparation described in Example I to post surgical sites twice a day for seven days. In both cases pain, inflammation and infection at the affected sites were relieved.
Example m Three patients exhibiting acne sores were instructed to apply the preparation described in Example I to the affected sites twice a day for seven days. In all cases, treatment with the preparations provided a reduction in the pain and inflammation associated with the sores.
Rxample IV
One patient undergoing radiation therapy and two patients undergoing chemotherapy were each instructed to apply the preparation described in Example I twice daily for one week. All three patients received relief from pain and showed faster healing rates of intraoral tissues following treatment with the prescribed preparations.
While ~rererred embodiments have been shown and described, various modifications and substitutions may be made without departing from the spirit and scope of the invention. For example, those skilled in the art will recognize that related derivatives of the active ingredients, such as pharmaceutically acceptable salts of chlorhexidine, and other prostaglandin inhibitors, such as flurbiprofen and naproxen, are useful in practicing the present invention
nFRl~AL PAIN, INFLAMMATION AND INFECTION
BACKGROUND OF I~F. INVENIION
The present invention relates generally to pharmaceutical preparations for the treatment of muco-epidermal and epidermal tissue.
More particularly, the present invention relates to gels, creams, solutions and other topical preparations including a mixture of chlorhexidine and at least one non-steroidal anti-iIlflAmmAtory agent. The invention further provides a method for the treatment of muco-epidermal and epitlermAl tissue using such preparations.
The antimicrobial effects of chlorhexidine are well-documented.
Chlorhexidine gels, rinses and creams are routinely used to control bacterial infections on mucosal epi-l~rmAl and epic~rmAl tissue. For example, chlorhexidine gels and rinses are widely used in dentistry for the treatment of periodontal disease. Non-steroidal anti-ir fl~mmAtory agents such as ibuprofen, ketoprofen and indomethacin have applicAtion in the treatment of, for example, inflAmmAtory diseases such as arthritis, general muscle, skeletal and joint pain and menstrual cramps.
While these compounds have been widely used individually by physicians and dentists in the above-described manner for many years, the effectiveness of a combination of chlorhexidine and a non-steroidal anti-i~flAmmAtory agent has not been appreciated.
Accordingly, it is the object of the present invention to provide a pharmaceutical preparation including a combination of chlorhexidine and at least one anti-i~flAmmAtory agent which together show a synergistic effect in the treatment of muco-epi~lermAl and epidermal irlflAmmAtion and infection.
It is a further object of the invention to provide a method for treating muco-epidermal and epidermal tissue using such preparations.
SUMMARY OF THE INVENTION
The present invention meets the above-stated objects and others that will become readily apparent by providing topical pharmaceutical preparations which include chlorhexidine and at least one non-steroidal anti-irflAmmAtory agent. These active ingredients are incorporated into a gel, cream, solution, rinse or other pharmaceutically acceptable carrier and are applied topically to sites of epi~1ermAl and muco-epidermal inflammation, infection or lesion.
wo 95/04520 æ~465 4~ PCT/US94/08944 The preparations which are the subject of the present invention include a non-toxic amount of chlorhexidine and preferably include, as the non-steroidal anti-inflammatory agent, indomethacin, ibuprofen, ketoprofen or other prostaglandin inhibitors.
As demonstrated below by the various examples provided, the combination of chlorhexidine and a non-steroidal anti-inflAmm~tory agent unexpectedly show a synergistic effect in the treatment of a number of conditions including, periodontal disease, acne, post-r~iAtion therapy, post-chemotherapy therapy, post-surgical therapy, burns and non-specific epidermal and muco-epidermal infections.
The present invention is also directed to a method for treating epi~rm~l and muco-epidermal tissue employing the above-described topical preparations. The course of therapy with such preparations generally requires one to three applications per day or is applied on an as needed basis, depending on the severity of the ronr~ition. Treatment includes directly applying the topical preparations to the affected site.
DRT~ D DF~ lONOF TH~ TION
As noted above, the-topical pharmaceutical preparations of the present invention include chlorhexidine in a therapeutically effective amount. For most therapies, from about 0.1 wt.% to about 1.0 wt.%, preferably about 0.2 wt.% of chlorhexidine, has been found to be effective. The preparations further include a non-toxic amount of at least one non-steroidal anti-inflammatory agent, most preferably indocin, ibuprofen and/or ketoprofen, in an amount ranging from about 2 wt.% to about 5 wt.% of the total preparation.
The active ingredients are incorporated into a solution, cream, rinse, lotion, gel or other acceptable carrier. In some instances, depending upon the particular carrier, the active ingredients are first solubilized and then incorporated into the carrier. The addition of a suspending agent to the carrier such as, for example, acacia powder, xanthan gum, methylcellulose, hydroxymethylcellulose or hydroxypropylcellulose, has been found to be particularly useful when compounding the carrier. In this regard, hydroxymethylcellulose gel is the ~reL~led carrier where treatment requires manual application of the preparation to affected epidermal or muco-epidermal tissue.
Fxample I
Ten patients exhibiting advanced periodontal disease were treated with a preparation of 0.2% chlorhexidine and 2% ketoprofen incorporated into a 2 ~ PCT/US94/08944 hydroxymethylcellulose gel. The patients were each instructed to apply one of the preparations to the affected gums with a tooth brush twice a day for a week. All of these patients experienced relief from pain, infection and inflammation after the prescribed course of therapy.
Fxample II
Two surgical patients were instructed to apply the preparation described in Example I to post surgical sites twice a day for seven days. In both cases pain, inflammation and infection at the affected sites were relieved.
Example m Three patients exhibiting acne sores were instructed to apply the preparation described in Example I to the affected sites twice a day for seven days. In all cases, treatment with the preparations provided a reduction in the pain and inflammation associated with the sores.
Rxample IV
One patient undergoing radiation therapy and two patients undergoing chemotherapy were each instructed to apply the preparation described in Example I twice daily for one week. All three patients received relief from pain and showed faster healing rates of intraoral tissues following treatment with the prescribed preparations.
While ~rererred embodiments have been shown and described, various modifications and substitutions may be made without departing from the spirit and scope of the invention. For example, those skilled in the art will recognize that related derivatives of the active ingredients, such as pharmaceutically acceptable salts of chlorhexidine, and other prostaglandin inhibitors, such as flurbiprofen and naproxen, are useful in practicing the present invention
Claims (14)
1. A topical pharmaceutical preparation for the treatment of epidermal and muco-epidermal tissue comprising a therapeutic amount of chlorhexidine and a non-toxic amount of at least one non-steroidal anti-inflammatory agent.
2. The topical preparation of claim 1 wherein the non-steroidal anti-inflammatory agent is a prostaglandin inhibitor.
3. The topical preparation of claim 1 wherein the non-steroidal anti-inflammatory agent is a prostaglandin inhibitor selected from the group consisting of indocin, ibuprofen, ketoprofen, flurbiprofen, naproxen and mixtures thereof.
4. The topical preparation of claim 1 wherein chlorhexidine is present in an amount ranging from about 0.1 wt.% to about 1.0 wt.% of the total preparation.
5. The topical preparation of claim 1 wherein the non-steroidal anti-inflammatory agent is present in an amount ranging from about 2 wt.%
to about 5 wt.% of the total preparation.
to about 5 wt.% of the total preparation.
6. The topical preparation of claim 1 wherein the preparation further comprises a pharmaceutical carrier incorporating the chlorhexidine and the non-steroidal anti-inflammatory agent.
7. The topical preparation of claim 6 wherein the carrier is selected from the group consisting of a solution, cream, rinse, lotion and gel.
8. A topical pharmaceutical preparation for the treatment of epidermal and muco-epidermal tissue comprising a therapeutic amount of chlorhexidine and at least one non-steroidal anti-inflammatory agent selected from the group consisting of indocin, ibuprofen, ketoprofen and mixtures thereof incorporated into a pharmaceutical carrier.
9. The topical preparation of claim 8 wherein the chlorhexidine is present in an amount ranging from about 0.1 wt.% to about 1.0 wt.% and the non-steroidal anti-inflammatory agent is present in an amount ranging from about 2 to about 5 wt.%.
10. The topical pharmaceutical preparation of claim 9 wherein the carrier is a gel.
11. A method for the treatment of epidermal and muco-epidermal tissue, said method comprising the steps of:
providing a topical pharmaceutical preparation including a carrier incorporating a therapeutic amount of chlorhexidine and a non-toxic amount of at least one non-steroidal anti-inflammatory agent, and applying the preparation directly to epidermal and muco-epidermal tissue having pain, inflammation, infection or lesion associated therewith.
providing a topical pharmaceutical preparation including a carrier incorporating a therapeutic amount of chlorhexidine and a non-toxic amount of at least one non-steroidal anti-inflammatory agent, and applying the preparation directly to epidermal and muco-epidermal tissue having pain, inflammation, infection or lesion associated therewith.
12. The method of claim 11 further characterized in that the non-steroidal anti-inflammatory agent is a prostaglandin inhibitor selected from the group consisting of indocin, ibuprofen, ketoprofen, flurbiprofen, naproxen and mixtures thereof.
13. The method of claim 11 further characterized in that the chlorhexidine is present in an amount ranging from about 0.1 wt.% to about 1.0 wt.% and the non-steroidal anti-inflammatory agent is present in an amount ranging from about 2 to about 5 wt.%.
14. The method of claim 11 further characterized in that the carrier is selected from the group consisting of a solution, cream, rinse, lotion and gel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10328993A | 1993-08-06 | 1993-08-06 | |
| US08/103,289 | 1993-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2146547A1 true CA2146547A1 (en) | 1995-02-16 |
Family
ID=22294404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002146547A Abandoned CA2146547A1 (en) | 1993-08-06 | 1994-08-08 | Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0664695A1 (en) |
| JP (1) | JPH08505402A (en) |
| CA (1) | CA2146547A1 (en) |
| WO (1) | WO1995004520A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888523A (en) * | 1997-09-22 | 1999-03-30 | Biocontrol, Inc. | Topical non-steroidal anti-inflammatory drug composition |
| GB2349644A (en) | 1999-05-01 | 2000-11-08 | Biointeractions Ltd | Infection resistant polymers, methods for their preparation, and their uses |
| FR2812190B1 (en) * | 2000-07-28 | 2003-01-31 | Oreal | USE OF NON-PROSTANOIC AGONISTS OF EP-2 AND / OR EP-4 PROSTAGLANDIN RECEPTORS AS A COSMETIC AGENT FOR MITIGATING, DECREASING OR STOPPING HAIR AND HAIR LOSS |
| FR2812192B1 (en) * | 2000-07-28 | 2003-01-31 | Oreal | USE OF PROSTAGLANDIN EP-3 RECEPTOR ANTAGONISTS AS A COSMETIC AGENT FOR MITIGATING, REDUCING OR STOPPING HAIR AND HAIR LOSS |
| GB0103668D0 (en) | 2001-02-15 | 2001-03-28 | Biointeractions Ltd | Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| FR2822070B1 (en) * | 2001-03-15 | 2006-01-06 | Andre Salkin | USE OF A BIGUANIDE DERIVATIVE AND A PYRIMIDINE FOR THE MANUFACTURE OF A COSMETIC CARE COMPOSITION |
| US8865198B2 (en) | 2010-10-25 | 2014-10-21 | Dexcel Pharma Technologies Ltd. | Method for treating a periodontal disease |
| RU2491061C2 (en) * | 2011-12-05 | 2013-08-27 | Елена Николаевна Светлакова | Agent for local treatment of periodontal diseases |
| WO2014027976A1 (en) | 2012-08-17 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Topical aqueous pharmaceutical compositions of flurbiprofen and chlorhexidine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8401965D0 (en) * | 1984-01-25 | 1984-02-29 | Beecham Group Plc | Composition |
| EP0159604B1 (en) * | 1984-04-09 | 1990-11-07 | Toyo Boseki Kabushiki Kaisha | Sustained-release preparation applicable to mucous membrane in oral cavity |
| JPS6160620A (en) * | 1984-09-03 | 1986-03-28 | Teijin Ltd | Pharmaceutical composition containing pyroglutamic acid ester |
| DE3686275T2 (en) * | 1985-01-11 | 1993-03-18 | Teijin Ltd | PREPARED PRODUCTS WITH DELAYED RELEASE. |
| JPS62223115A (en) * | 1986-03-25 | 1987-10-01 | Rooto Seiyaku Kk | Remedy for periodontosis |
| US4975271A (en) * | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
| US5230895A (en) * | 1990-05-01 | 1993-07-27 | Copley Pharmaceutical Inc. | Sustained released delivery system for use in the periodontal pocket |
| US5102666A (en) * | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
-
1994
- 1994-08-08 CA CA002146547A patent/CA2146547A1/en not_active Abandoned
- 1994-08-08 WO PCT/US1994/008944 patent/WO1995004520A1/en not_active Application Discontinuation
- 1994-08-08 EP EP94924605A patent/EP0664695A1/en not_active Withdrawn
- 1994-08-08 JP JP7506565A patent/JPH08505402A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0664695A1 (en) | 1995-08-02 |
| JPH08505402A (en) | 1996-06-11 |
| WO1995004520A1 (en) | 1995-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU777821B2 (en) | Therapeutic compositions and methods of use thereof | |
| EP1272152B1 (en) | Use of chlorhexidine in the prevention of root caries | |
| JP2007513162A (en) | Compositions and methods for topical treatment of skin infections | |
| WO2009106963A2 (en) | Dental composition for preventing and treating stomatitis and mouth ulcers | |
| WO2003103691A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
| JPH0597668A (en) | Treatment of gum inflammation | |
| Alleyn et al. | The effect of chlorhexidine treatment of root surfaces on the attachment of human gingival fibroblasts in vitro | |
| CA2146547A1 (en) | Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection | |
| US4518583A (en) | Hemorrhoid and anorectal disease treatment method | |
| US5167952A (en) | Therapeutic composition formulated as a dental rinse that stimulates Prostaglandin synthesis in the mouth to prevent plaque buildup on the teeth and Periodontal disease | |
| RU2184538C2 (en) | Use of dichlorobenzyl alcohol for preparing medicinal agent for treatment of topical inflammation and medicinal agent comprising dichlorobenzyl alcohol | |
| US4985235A (en) | Treatment of periodontoclasia with retinoic acid | |
| JPH06211636A (en) | Composition for oral cavity application | |
| JP2887636B2 (en) | Oral preparation | |
| JPH08133969A (en) | Alveolar bone resorption inhibitor | |
| JPS6054932B2 (en) | therapeutic composition | |
| WO1983000628A1 (en) | A method of treating acne vulgaris and composition containing carbamide peroxide | |
| JPH07247210A (en) | Composition for oral cavity | |
| CA2524921A1 (en) | Method and composition for treating burned skin | |
| CA1337931C (en) | Treatment of periodontoclasia with retinoic acid | |
| JPH0637383B2 (en) | Oral anti-inflammatory agent | |
| JPH10298045A (en) | Composition for oral cavity | |
| JPH09175967A (en) | Composition for oral cavity | |
| JPH0769851A (en) | Composition for oral cavity | |
| WO1987003476A1 (en) | Composition for the treatment of periodontal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 19980810 |